Skip to Main content Skip to Navigation

Développement d’une seconde génération de nanoparticules AGuIX pour des applications théranostiques en oncologie

Abstract : With 8.8 million deaths in 2015, cancer is the second leading cause of death in the world and the number of new cases should continue to increase in the decades to come. It is therefore essential to develop new tools for the diagnosis and therapy of this disease. In this context, the Institute of Light and Matter has developed a nanoparticle called AGuIX® (Activation and Guidance of Irradiation X). With a size below 5 nm, it is made of gadolinium chelates covalently grafted to a polysiloxane core. Thanks to these complexes, the nanoparticle can be used as a contrast agent for Magnetic Resonance Imaging (MRI) and can improve the radiotherapy efficacy (radiosensitizing effect).The goal of this PhD is to develop a second generation of AGuIX® nanoparticles to allow even more precise diagnosis or even more effective therapies. For this, we focused on: (i) improving the radiosensitizing effect of this nanoplateform by adding bismuth complexes to its surface; (ii) complexing various radiometals to enable the NPs detection by scintigraphy; (iii) functionalizing the NPs for MRI-guided photodynamic therapy. In all cases, after optimization of the syntheses, various characterization techniques were put in place to obtain an accurate description of the particles. The effectiveness of these new nano-objects for the diagnosis and/or treatment of cancers was then evaluated thanks to several collaborations, in France or internationally
Document type :
Complete list of metadatas
Contributor : Abes Star :  Contact
Submitted on : Tuesday, January 2, 2018 - 2:06:45 AM
Last modification on : Thursday, October 15, 2020 - 8:54:03 AM
Long-term archiving on: : Wednesday, May 2, 2018 - 6:45:38 PM


Version validated by the jury (STAR)


  • HAL Id : tel-01674228, version 1



Eloïse Thomas. Développement d’une seconde génération de nanoparticules AGuIX pour des applications théranostiques en oncologie. Cancer. Université de Lyon, 2017. Français. ⟨NNT : 2017LYSE1121⟩. ⟨tel-01674228⟩



Record views


Files downloads